← Eichor
Condition: Unresectable Colon Cancer Peritoneal Metastases Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Unresectable Colon Cancer Peritoneal Metastases

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT05742425
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.